Company Filing History:
Years Active: 2019-2022
Title: Innovations by Joyce Ching Chou
Introduction
Joyce Ching Chou is a prominent inventor based in Sunnyvale, CA (US). She has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies and chimeric antigen receptors. With a total of 4 patents to her name, her work has the potential to impact cancer treatment significantly.
Latest Patents
One of her latest patents is titled "Antibodies specific for epidermal growth factor receptor variant III and their uses." This invention provides antibodies that specifically bind to EGFRvIII (Epidermal Growth Factor Receptor Variant III). The invention also includes bispecific antibodies that bind to EGFRvIII and another antigen, such as CD3, along with antibody conjugates. Furthermore, it relates to antibody encoding nucleic acids and methods for obtaining these antibodies and conjugates. The therapeutic methods outlined in this patent aim to treat EGFRvIII-mediated pathologies, including cancers like glioblastoma.
Another significant patent by Chou is "Chimeric antigen receptors targeting epidermal growth factor receptor variant III." This invention offers Chimeric Antigen Receptors (CARs) that specifically bind to EGFRvIII. It also discusses engineered immune cells that comprise such CARs, CAR-encoding nucleic acids, and methods for their production. The therapeutic applications of these CARs and engineered immune cells are aimed at treating EGFRvIII-mediated pathologies, including glioblastoma.
Career Highlights
Joyce Ching Chou is currently employed at Pfizer Corporation, where she continues to innovate in the field of biotechnology. Her work is characterized by a strong focus on developing novel therapeutic approaches for cancer treatment.
Collaborations
Chou collaborates with notable colleagues, including Oi Kwan Wong and Barbra Johnson Sasu, who contribute to her research and development efforts.
Conclusion
Joyce Ching Chou's innovative work in developing antibodies and chimeric antigen receptors showcases her commitment to advancing cancer therapies. Her contributions are paving the way for new treatment options for patients suffering from EGFRvIII-mediated cancers.